Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

otease inhibitor compound RG7227/ ITMN-191 in Phase 2b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors disc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... National Dementia Screening Policy , , ... the nation faces a public health crisis related to ... the Alzheimer,s Foundation of America (AFA) disputes an ongoing ... The report shatters unsubstantiated criticism and instead emphasizes the ...
... Non-Contact Medical Device Innovations - the Future of Patient ... in Outer Space , , ... Noninvasive Medical Technologies, Inc. (NMT), a medical device company ... for military and civilian medical use, today announced that ...
... /PRNewswire-Asia-FirstCall/ -- China Shenghuo,Pharmaceutical Holdings, Inc. (NYSE Alternext ... that the Company is expanding its herbal-based,"12 Ways" ... markets in Mainland China. , ... its "12 Ways" brand of cosmetics products,to eleven ...
... PatentStorm, the searchable website of millions of U.S. patents, has expanded ... applications. PatentStorm has also completed a host of other improvements, making ... ... Washington, DC (PRWEB) December 9, 2008 -- PatentStorm ...
... China, Dec. 9 /PRNewswire-Asia-FirstCall/ -- China Sky One ... (Nasdaq: CSKI ), a leading,fully integrated ... of China ("PRC"), announced today that its subsidiary,Peng ... production approval from the State Food and Drug ...
... for Low-dose, Weekly Contraceptive Patch to be Presented at ACOG ... , PRINCETON, N.J., Dec. 9 Agile ... products, today announced that two abstracts from Phase 2 studies ... by the American College of Obstetricians and Gynecologists Annual ...
Cached Medicine News:Health News:New Study Disputes Ongoing Controversy Over Memory Screenings 2Health News:New Study Disputes Ongoing Controversy Over Memory Screenings 3Health News:New Study Disputes Ongoing Controversy Over Memory Screenings 4Health News:U.S. Air Force Awards Noninvasive Medical Technologies $2.4 Million Contract 2Health News:U.S. Air Force Awards Noninvasive Medical Technologies $2.4 Million Contract 3Health News:China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores 2Health News:China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores 3Health News:China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores 4Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 2Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 3Health News:Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG 4
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... July 12 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... offer by its wholly owned subsidiary, HT Acquisition Corp., for all ... HTRN).  American Stock Transfer & Trust Company, the depositary for the ... , New York City time, on July 9, ...
... 12 Signum Biosciences announced that its ... Medirepair® with Signum,s compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) ... compound from Signum,s novel anti-inflammatory platform to be ... (STMs). The DRx AFC Medirepair® website can be ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 2Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 3Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 4Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 2Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 3
... a simple click of the mouse ... mouse cursor to the desired position ... slide and the magnified image is ... Interface (GUI) enables one-click operation of ...
... new Eclipse TS100 is an ... microscope. This high quality tool ... mechanics and increased stability - ... rigid vibration resistant design that ...
Carbide drill bits, cutters, side cutting. Available in various sizes....
... the enclosed polaroid glasses, these polarized ... devise for near point stereopsis which ... perception, the images appear to pop ... test includes circle patterns for depth ...
Medicine Products: